Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA3 | P32297 | 5/20 | 0.54 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.48 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.48 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.40 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | PDCD1LG2 | Q9BQ51 | 2/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7405130 | 0.80 | SLC6A2 (0.39) | CHRNA3CHRNB2CHRNA4SLC6A2SLC6A4 | |
| SCHEMBL4961589 | 0.80 | SLC6A2 (0.39) | CHRNA3CHRNB2CHRNA4SLC6A2SLC6A4 | |
| SCHEMBL7408811 | 0.80 | SLC6A2 (0.39) | CHRNA3CHRNB2CHRNA4SLC6A2SLC6A4 | |
| SCHEMBL8550597 | 0.79 | SLC6A2 (0.35) | CHRNA3CHRNB2CHRNA4CHRNB4SLC6A2 | |
| Hydrochloric Acid SCHEMBL7406975 | 0.79 | CHRNB2 (0.38) | CHRNA3CHRNB2CHRNA4SLC6A2SLC6A4 | |
| SCHEMBL8554864 | 0.79 | SLC6A2 (0.35) | CHRNA3CHRNB2CHRNA4CHRNB4SLC6A2 | |
| Hydrochloric Acid SCHEMBL7410705 | 0.79 | CHRNB2 (0.38) | CHRNA3CHRNB2CHRNA4SLC6A2SLC6A4 | |
| SCHEMBL7417197 | 0.78 | CHRNA3 (0.41) | CHRNA3CHRNB2CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL7408878 | 0.78 | CHRNB2 (0.37) | CHRNB2CHRNA4PDCD1LG2CD274 | |
| SCHEMBL8550798 | 0.78 | CHRNB2 (0.37) | CHRNB2CHRNA4PDCD1LG2CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176826-A1 | Pyridine Compounds For Combating Arthropod Pests and Nematodes | BASF AKTIENGESELLSCHAFT (DE) | 2008-07-24 | — | — | US | disclosed |
| EP-1891045-A2 | PYRIDINE COMPOUNDS FOR COMBATING ARTHROPOD PESTS AND NEMATODES | BASF AKTIENGESELLSCHAFT (DE) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006125641-A2 | PYRIDINE COMPOUNDS FOR COMBATING ARTHROPOD PESTS AND NEMATODES | BASF AKTIENGESELLSCHAFT (DE) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176826-A1 | Pyridine Compounds For Combating Arthropod Pests and Nematodes | C5, CHRM1, ACHE | CHRNA3 364/4885CHRNB2 679/4885CHRNA4 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.